ChatAbout Prof. Dr. med. Mechthild Krause
- Prof. Dr. med. Mechthild Krause is a radiation oncologist with 12+ years of experience.
- Her main areas of professional interest include radiation therapy for brain tumors and breast tumor.
- She is a member of ESTRO and DEGRO.
- She has won the VARIAN-Juliana Denekamp Award of the European Society for Radiotherapy Oncology (ESTRO) 2005 and the Hermann Holthusen Award of the DEGRO.
- Dr. Krause completed her graduation from Technische University in Dresden, Germany.
- She has numerous publications in international high-ranking journals.
Hospital
Location
LocationDresden, Germany
Special Interest
Brain tumor, Breast tumor
Work Experience of Prof. Dr. med. Mechthild Krause
Visiting Consultant, Princess Margaret Hospital, University of Toronto
Senior Resident, University Hospital C.G. Carus, Dresden
Prof. Dr. med. Mechthild Krause's
- Graduation, 2000, Technische University Dresden, Germany
- Lühr A, Löck S, Roth K, Helmbrecht S, Jakobi A, Petersen JP, Just U, Krause M, Enghardt W, Baumann M (2014) Concept for Individualized Patient Allocation: ReCompare - Remote Comparison of Particle and Photon Treatment Plans. Radiat Oncol 9, 59
- Koch U, Höhne K, von Neubeck C, Thames HD, Yaromina A, Dahm-Daphi J, Baumann M, Krause M (2013) Residual-H2AX foci predict local tumour control after radiotherapy. Radiother Oncol 108, 434-39
- Gurtner K, Deuse Y, Bütof R, Schaal K, Eicheler W, Oertel R, Grenman R, Thames HD, Yaromina A, Baumann M, Krause M (2011) Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 99, 323-30
- Baumann M, Krause M (2010): CD44 - A Cancer Stem Cell-Related Biomarker with Predictive Potential for Radiotherapy. Clinical Cancer Research 16, 5091-93, 2010
- Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8(7): 545-54.
- Krause M, Baumann M (2008). Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metast Rev, 27, 387-402.
- Krause M, Prager J, Zhou X, Yaromina A, Dörfler A, Eicheler W, Baumann M (2007). EGFR-inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumorigenic cells? Radiother Oncol 83, 316-325
- Krause M, Zips D, Thames HD, Kummermehr J, Baumann M (2006) Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother. Oncol. 80: 112-122.
- Krause M, Schütze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M (2005) Different classes of EGFR inhibitors may have different potential to improve local tumor control after fractionated irradiation: A study on C225 in FaDu hSCC. Radiother Oncol 74: 109-115.
- Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, Harstrick A, van der Kogel A, Thames HD, Baumann M (2005) Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76, 162-167
Wondering where to start?
(Get Free opinion, Quote, Medical Visa Invitation and Assistance at every step of your treatment.)
Doctor Similar to Prof. Dr. med. Mechthild Krause in Dresden
Prof. med. Dr. Esther Troost
Radiation Oncologist
Senior Consultant
Graduation,Post Graduation
Dresden, Germany
17 years of experience
